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Abstract
AIM: To assess the combined effect of disease 
phenotype, smoking and medical therapy [steroid, 
azathioprine (AZA), AZA/biological therapy] on the 
probability of disease behavior change in a Caucasian 
cohort of patients with Crohn’s disease (CD).
METHODS: Three hundred and forty well-characterized, 
unrelated, consecutive CD patients were analyzed (M/F: 
155/185, duration: 9.4 ± 7.5 years) with a complete 
clinical follow-up. Medical records including disease 
phenotype according to the Montreal classification, 
extraintestinal manifestations, use of medications and 
surgical events were analyzed retrospectively. Patients 
were interviewed on their smoking habits at the time of 
diagnosis and during the regular follow-up visits. 
RESULTS: A change in disease behavior was observed 
in 30.8% of patients with an initially non-stricturing, 
non-penetrating disease behavior after a mean disease 
duration of 9.0 ± 7.2 years. In a logistic regression 
analysis corrected for disease duration, perianal 
disease, smoking, steroid use, early AZA or AZA/
biological therapy use were independent predictors of 
disease behavior change. In a subsequent Kaplan-Meier 
survival analysis and a proportional Cox regression 
analysis, disease location (P  = 0.001), presence of 
perianal disease (P  < 0.001), prior steroid use (P = 
0.006), early AZA (P  = 0.005) or AZA/biological therapy 
(P  = 0.002), or smoking (P  = 0.032) were independent 
predictors of disease behavior change.
CONCLUSION: Our data suggest that perianal 
disease, small bowel disease, smoking, prior steroid 
use, early AZA or AZA/biological therapy are all 
predictors of disease behavior change in CD patients.
© 2009 The WJG Press and Baishideng. All rights reserved.
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INTRODUCTION
Inflammatory bowel disease (IBD) is a multifactorial 
disease with probable genetic heterogeneity[1]. In 
addition, several environmental risk factors (e.g. diet, 
smoking, measles or appendectomy) may contribute to 
its pathogenesis. During the past decades, the incidence 
pattern of  both forms has significantly changed[2], 
showing some common but a lso qui te d is t inct 
characteristics for the two disorders. 
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Phenotypic classification of  Crohn’s disease (CD) 
plays an important role in determining treatment and 
may assist in predicting the likely clinical course of  dis-
ease[3]. In 2005, the Montreal revision of  the Vienna 
classification system was introduced[4]. Although the 
broad categories for CD classification remained the 
same, changes were made within each category. Upper 
gastrointestinal disease can now exist independently of, 
or together with, disease present at more distal locations. 
Finally, perianal disease, which occurs independently of  
small bowel fistulae, is no longer classified as penetrating 
disease. Instead, a perianal modifier has been introduced, 
which may coexist with any disease behavior. 
Using the Vienna classification system, it has been 
shown in clinic-based cohorts that there can be a signifi-
cant change in disease behavior over time, whereas dis-
ease location remains relatively stable[3,5]. An association 
between the presence of  perianal disease and internal 
fistulation (OR: 2.6-4.6) was reported earlier by Sachar 
et al[6] in patients with colonic disease. Most recently, 
Australian authors[3] have shown that although > 70% 
of  CD patients had inflammatory disease at diagnosis, 
the proportion of  patients with complicated disease 
increased over time. Progression to complicated disease 
was more rapid in those with small bowel than colonic 
disease location (P < 0.001), with perianal disease being 
also a significant predictor of  change in CD behavior 
(HR: 1.62, P < 0.001). Similarly, small bowel location 
and stricturing disease were predictors for surgery in a 
long-term follow-up study[7]. Finally, perianal lesions, 
the need for steroids to treat the first flare-up and ileo-
colonic location, but not an age below 40 years were 
confirmed as predictive markers for developing disabling 
disease (according to the predefined criteria) at 5 years[8]. 
In the same study, stricturing behavior (HR: 2.11, 95% 
CI: 1.39-3.20) and weight loss (> 5 kg) (HR: 1.67, 95% 
CI: 1.14-2.45) at diagnosis were independently associated 
with the time to development of  severe disease.
A further environmental factor which may be of  
importance in determining change in disease behavior is 
smoking. In CD, smoking was reported to be associated 
with disease location: most, but not all, studies report a 
higher prevalence of  ileal disease and a lower prevalence 
of  colonic involvement in smokers[9,10]. A recent review[10] 
and previous data have demonstrated that smoking, when 
measured up to the time-point of  disease behavior classi-
fication, was more frequently associated with complicated 
disease and penetrating intestinal complications[9,11,12], a 
greater likelihood of  progression to complicated disease, 
as defined by the development of  strictures or fistu-
lae[10], and a higher relapse rate[13]. In addition, the risk of  
surgery as well as the risk for further resections during 
disease course were also noted to be higher in smokers in 
some studies[9,14] and a recent meta-analysis[15]. The need 
for steroids and immunosuppressants was found to be 
higher in smokers compared to non-smokers[16]. Note-
worthy, in one study by Cosnes et al[17], immunosuppres-
sive therapy was found to neutralize the effect of  smok-
ing on the need for surgery. In a recent paper by Aldhous 
et al[18], using the Montreal classification, the harmful 
effect of  smoking was only partially confirmed. Although 
current smoking was associated with a lower rate of  co-
lonic disease, the smoking habits at diagnosis were not as-
sociated with time to development of  stricturing disease, 
internal penetrating disease, perianal penetrating disease, 
or time until first surgery. 
Finally, early postoperative use of  azathioprine (AZA, 
at a dose of  2-2.5 mg/kg per day) appeared to delay 
postoperative recurrence in comparison to a historical 
series or placebo groups in randomized, controlled tri-
als[19]. Furthermore, in a recent withdrawal study by the 
GETAID group[20], the authors provide evidence for 
the benefit of  long-term AZA therapy beyond 5 years 
in patients with prolonged clinical remission. In con-
trast, initial requirement for steroid use [OR: 3.1 (95% 
CI: 2.2-4.4)], an age below 40 years (OR: 2.1, 95% CI: 
1.3-3.6), and the presence of  perianal disease (OR: 1.8, 
95% CI: 1.2-2.8) were associated with the development 
of  disabling disease in the study by Beaugerie et al[21] The 
positive predictive value of  disabling disease in patients 
with two and three predictive factors for disabling dis-
ease was 0.91 and 0.93, respectively.
In this study, the authors aimed to assess the 
combined effect of  disease phenotype, smoking, and 
medical therapy (steroid, AZA, AZA/biological) on the 
probability of  disease behavior change in a cohort of  
Hungarian CD patients.
MATERIALS AND METHODS
Patients
Three hundred and forty well-characterized, unrelated, 
consecutive CD patients (age: 38.1 ± 13.2 years, M/F: 
155/185, duration: 9.4 ± 7.5 years) with a complete clini-
cal follow-up were included. A detailed clinical pheno-
typic description of  these patients is presented in Table 1.
The diagnosis was based on the Lennard-Jones 
Criteria[22]; age, age at onset, presence of  familial IBD, 
presence of  extraintestinal manifestations; arthritis: 
peripheral and axial; ocular manifestations: conjunctivitis, 
uveitis, iridocyclitis; skin lesions: erythema nodosum, 
pyoderma gangrenosum; and hepatic manifestations: 
primary sclerosing cholangitis, frequency of  flare-ups 
(frequent flare-up: > 1 per year). The disease phenotype 
(age at onset, duration, location, and behavior) was 
determined according to the Montreal Classification[4] 
(non-inflammatory behavior: either stricturing or 
penetrating disease). Perianal disease and behavior 
change during follow-up were also registered. Medical 
therapy was registered in detail [e.g. steroid and/or 
immunosuppressive/biological therapy use, AZA 
intolerance as defined by the ECCO (European Crohn’s 
and Colitis Organisation) Consensus Report[23]], need 
for surgery/reoperation (resections) in CD, and time-
point of  surgery/reoperation and smoking habits, 
were investigated by reviewing the medical charts 
and completing a questionnaire. Only patients with a 
confirmed diagnosis for more than 1 year were enrolled. 
Definitions of  AZA/biological therapy use and 
smoking: patients were regarded as AZA users if  they 
took a dose of  ≥ 1.5 mg/kg body weight for at least 
6 mo. Early use was considered if  the use of  immuno-
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modulatory therapy preceded the behavior change by at 
least 6 mo. According to the Center’s policy, if  AZA was 
started, its use was not halted even in patients with long-
term clinical remission. The rate of  AZA intolerance 
was 14.3% (including 36 additional patients), and these 
patients were classified as AZA-non-users. Common 
intolerance reactions were leukopenia, abdominal pain, 
and in three patients, pancreatitis. Biological therapy use 
was considered if  the patient received at least a full, anti-
tumor necrosis factor induction therapy at an appropriate 
dose. The definition of  smoking consisted of  smoking 
≥ 7 cigarettes/wk for at least 6 mo[15-18] at the time of  
diagnosis and/or during follow-up, within 1 year of  di-
agnosis or behavior change. Patients were interviewed on 
their smoking habits at the time of  diagnosis and during 
the regular follow-up visits. Moreover, due to Hungarian 
health authority regulations, a follow-up visit is obligatory 
for IBD patients at a specialized gastroenterology centre 
every 6 mo. Otherwise, the conditions of  the health in-
surance policy change and they forfeit their ongoing sub-
sidized therapy. Consequently, the relationship between 
the IBD patients and their specialists is a close one. The 
referred patients were retrospectively interviewed about 
their smoking habits at the time of  referral and thereafter. 
Smoking cessation was defined as complete abstinence 
of  at least 1 year’s duration. Only 16 (4.7%) CD patients 
stopped smoking during the course of  the disease, while 
2 additional CD patients started smoking after the diag-
nosis. In patients with change in disease behavior, all CD 
patients stopped smoking following the change. Since 
macroscopic lesions on the ileal side of  the anastomosis 
observed 1 year following surgery were not different be-
tween smokers and non-smokers and there was no signif-
icant difference reported between ex-smokers and non-
smokers in reoperation rates in a recent meta-analysis [15,24], 
ex-smokers at the time of  diagnosis were included in the 
non-smoker group.
Detailed clinical phenotypes were determined by 
thoroughly reviewing the patients’ medical charts, which 
had been collected in a uniform format. The central 
coordination of  sample and database management was 
completed at the 1st Department of  Medicine, Semmelweis 
University (by PLL, TS). Data capture was prospective 
except for referred patients in whom disease course 
until referral was registered at the date of  the referral 
and prospectively thereafter. Data analysis was done 
retrospectively. The study was approved by the Semmelweis 
University Regional and Institutional Committee of  Science 
and Research Ethics.
Statistical analysis
Variables were tested for normality using Shapiro Wilk’s 
W test. The t-test with separate variance estimates, 
ANOVA with post hoc Scheffe test, χ2-test, and χ2-test with 
Yates correction were used to evaluate differences within 
subgroups of  IBD patients. Kaplan-Meier survival curves 
were plotted for analysis with the LogRank and Breslow 
tests. Additionally, forward stepwise Cox regression 
analysis was used to assess the association between 
categorical clinical variables and surgical requirements. P 
< 0.05 was considered as significant. For the statistical 
analysis, SPSS 15.0 (SPSS Inc, Chicago, IL) was used with 
the assistance of  a statistician (Dr. Peter Vargha).
RESULTS
Association between clinical markers and disease 
behavior change in CD patients
In a univariate analysis, behavior change from B1 to B2/
B3 during follow-up was associated with disease dura-
tion, location, presence of  perianal disease, smoking at 
diagnosis, frequency of  relapses, steroid use, early AZA 
use, AZA/biological therapy use and need for resective 
surgery (Table 2). Although ocular manifestations were 
also associated with behavior change (3.6% vs 11.5%, 
P = 0.033), this became non-significant after Bonferroni 
correction. Patients with a change in disease behavior 
had significantly longer disease duration (12.3 ± 7.6 years 
vs 7.4 ± 6.5 years, P < 0.001).
In a logistic regression model, disease duration, 
presence of  perianal disease, smoking, steroid use, and 
early AZA use prior to behavior change were independent 
predictors for change in disease behavior (Table 3). 
If  early AZA use was changed to early AZA and/or 
biological therapy use (Coefficient: -1.221, P = 0.002, OR: 
0.29, 95% CI: 1.34-0.64) in the same logistic regression 
model, the associations remained unchanged. 
CD (n  = 340)
Male/female 155/185
Age (yr) 38.1 ± 13.2
Age at presentation (yr) 28.7 ± 12.4
Duration (yr) 9.4 ± 7.5
Familial IBD   39 (11.4)
Location
   L1   75
   L2   99
   L3 161
   All L4   22
   L4 only     5
Behavior at diagnosis
   B1 198
   B2   65
   B3   77
Behavior change from B1 to B2/B3   61 (30.8)
Perianal disease 117 (34.4)
Frequent relapse 126 (37.1)
Arthritis 127 (37.5)
PSC 10 (2.9)
Ocular 17 (5.0)
Cutaneous   43 (12.6)
Steroid use 264 (77.6)
Azathioprine use 216 (63.5) 
Azathioprine intolerance   36 (14.3)
Biological use   71 (20.9)
Surgery/reoperation 158 (46.5)/52 (32.8)
Smoking habits
   No 151
   Ex   36
   Yes 153
L1: Ileal; L2: Colonic; L3: Ileocolonic; L4: Upper gastrointestinal disease; 
B1: Inflammatory; B2: Stenosing; B3: Penetrating disease behavior. IBD: 
Inflammatory bowel disease.
Table 1  Clinical characteristics of patients with Crohn’s 
disease  n  (%)
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Association between clinical markers and time to 
disease behavior change in CD patients 
Disease location, perianal disease, early AZA or AZA/
biological therapy, steroid use (LogRank P = 0.004 
and Breslow P = 0.005) and smoking were significant 
determinants for time to behavior change surgery in a 
Kaplan-Meier analysis using LogRank and Breslow tests 
(Figure 1). 
To further evaluate the effect of  the above variables 
on the probability of  behavior change, we performed a 
forward stepwise proportional Cox regression analysis. 
Each of  the above variables was independently associated 
with the probability of  disease behavior change (Table 4). 
The result was the same if  early AZA/biological therapy 
use (P = 0.002, HR: 0.43, 95% CI: 0.25-0.73) was incor-
porated in the same analysis.
DISCUSSION
In the present study, we assessed, for the first time, 
the combined effect of  disease phenotype and medical 
therapy on the probability of  disease behavior change 
in a well-characterized CD cohort with a strict clinical 
follow-up. This study has shown that perianal disease, 
disease location, prior steroid, early AZA or AZA/bio-
logical therapy were significant independent predictors 
of  disease behavior change during follow-up in patients 
with CD, in a stepwise proportional Cox regression and 
Kaplan-Meier analysis. 
In accordance with the findings by Tarrant et al[3], 
the presence of  perianal disease was associated with 
a 3-4-fold increased risk of  developing complicated 
disease behavior in patients with non-stricturing, non-
penetrating disease at the time of  diagnosis. Interestingly, 
in both studies, approximately 50%-55% of  patients 
with perianal disease and only 15%-20% of  patients 
without perianal disease developed a complicated disease 
behavior after 10 years of  follow-up. In the present 
study, however, only 60% of  the patients presented 
with B1 behavior, representing the more severe 
disease population in referral centers. In contrast, the 
Australian study reports the results of  a population-
based cohort follow-up. Therefore, our results are not 
only confirmatory, but enable us to extrapolate on the 
finding that perianal disease is a poor prognostic factor 
in referral center IBD populations. 
In addition, similar to the Australian study, the 
present study found that progression to complicated 
disease was more rapid in those with small bowel than 
colonic disease location. The HR was significantly lower 
(0.54, P = 0.05) for colonic disease and significantly 
higher for ileal disease (2.13, P = 0.023) compared to an 
ileocolonic location in the Cox regression analysis. The 
same conclusions were reached when data were analyzed 
Table 2  Clinical factors associated with behavior change from inflammatory to complicated disease behavior  n (%)
Factor Prevalence without 
behavior change 
Prevalence with 
behavior change 
P -value OR 95% CI
Disease location
   L1    19 (13.9)    17 (27.9)
   L2    55 (40.1)    18 (29.5)  0.04 - -
   L3 63 (46) 25 (41)
   L4                  0    1 (1.6)
Perianal disease    30 (22.2)    30 (49.2) < 0.001 3.4 1.78-6.46
Frequent relapses    18 (13.1)    19 (31.1)    0.003 3.0 1.43-6.23
Disease duration (> 10 yr)    28 (20.4)    35 (57.4) < 0.001 5.3   2.7-10.1
Smoking    51 (37.2)    32 (52.5)  0.04 1.9 1.02-3.45
Steroid use  106 (77.4)    59 (96.7)    0.001 8.6 2.00-37.3
Early azathioprine use    79 (57.7)    24 (39.3)    0.017   0.48 0.26-0.88
Early azathioprine/biological use    83 (60.6) 25 (41)  0.01   0.45 0.24-0.84
Need for operation    19 (13.9)    37 (60.7) < 0.001 9.6 4.72-19.4
Table 3  Logistic regression: predictive factors for behavior 
change from non-stricturing, non-penetrating to complicated 
disease behavior in Crohn’s disease
Factor Coefficient P -value OR 95% CI
Disease location -0.385   0.13 - -
Longer disease duration 
(≤ 10 yr vs > 10 yr)
 1.476 < 0.001 4.37 2.04-9.38
Perianal disease  1.351    0.001 3.86 1.72-8.67
Frequent relapses  0.388    0.404 - -
Smoking  1.015    0.009 2.76 1.29-5.89
Steroid use  2.089  0.01 8.07 1.64-39.7
Early azathioprine use -1.055    0.006 0.35 0.16-074
The coefficient is equivalent to the natural log of the OR.
Table 4  Summary of Cox regression model: factors affecting 
time to disease behavior change
P -value Hazard ratio 95% CI
Disease location    0.001
   L1    0.023 2.13 1.11-4.08
   L2  0.05 0.54   0.27-1.001
   L3 Reference
Perianal disease
   Yes < 0.001 3.26 1.90-5.59
   No Reference
Steroid use
   Yes    0.006 7.48 1.79-31.2
   No Reference
Early azathioprine use
   Yes    0.005 0.46 0.27-0.79
   No Reference
Smoking status
   Yes    0.032 1.79 1.05-3.05
   No Reference
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by the Kaplan-Meier method using the LogRank and 
Breslow tests for comparison. Of  note, while the L1 and 
L3 curves ran parallel after 150 mo, the relatively small 
number of  patients in the L1 group may have introduced 
a bias in the analysis. These results were only partially 
confirmed by Aldhous et al [18]. In 275 CD patients, 
colonic disease was negatively associated with the time 
required for development of  stricturing complications 
(P < 0.001), while any upper gastrointestinal disease 
(and tendentially ileocolonic disease, P = 0.066) was 
the only factor significantly increasing the risk of  
development of  fistulizing complications. Finally, small 
bowel involvement, stricturing disease, and a young age 
at diagnosis were associated with disease recurrence in 
another Dutch population-based study[7].
In the present study, we could not confirm frequency 
of  relapses as an independent prognostic factor for 
disease behavior change. This is somewhat in contrast 
with the findings by Munkholm et al[25], where the relapse 
rate within a year of  diagnosis and in the following 
2 years, was positively correlated (P = 0.00001) with the 
relapse rate in the following 5 years in patients with CD. 
The findings were slightly different if  the authors 
assessed the clinical factors associated with the develop-
ment of  irreversible structural damage. After a multivari-
ate analysis, only stricturing behaviour at diagnosis (HR: 
2.11, P = 0.0004) and weight loss (> 5 kg) at diagnosis 
(HR: 1.67, P = 0.0089) were independently associated 
with time to the development of  severe disease in the 
study by Loly et al[8]. The definition of  severe, non-
reversible damage was, however, much more rigorous. 
It was defined by the presence of  at least one of  the 
following criteria: the development of  complex perianal 
disease, any colonic resection, two or more small-bowel 
resections (or a single small-bowel resection measur-
ing more than 50 cm in length) or the construction of  
a definite stoma. Nonetheless, medical therapy was not 
included in either of  the previous studies.
Similarly, although the effect of  smoking was 
extensively investigated in IBD, most studies failed to 
investigate the complex associations between smoking, 
disease phenotype, and medical therapy. A recent review[10] 
and previous data have demonstrated that current 
smoking was more frequently associated with complicated 
disease, penetrating intestinal complications[9,10], and 
greater likelihood to progress to complicated disease, as 
defined by the development of  strictures or fistulae[11]. 
In accordance, in the present study, smoking at the time 
of  diagnosis was independently associated with time to 
behavior change from a non-stricturing, non-penetrating 
phenotype to complicated disease behavior in CD in a 
Cox regression model. 
Figure 1  Association between disease location (A), perianal disease (B), early azathioprine/biological therapy use (C) or smoking (D) and disease behavior 
change from non-stricturing, non-penetrating to complicated disease behavior in Crohn’s disease.
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However, this was not a universal finding. In a recent 
paper by Aldhous et al[18], using the Montreal classifica-
tion, the harmful effect of  smoking was only partially 
confirmed. Although current smoking was associated 
with less colonic disease, the smoking habits at diagnosis 
were not associated with time to development of  strictur-
ing disease, internal penetrating disease, perianal penetrat-
ing disease, or time to first surgery. In contrast, disease 
location was associated with the need for surgery.
A more solid end-point was also deleteriously affected 
by smoking in the present study; the need for intestinal 
resection but not reoperation was also increased in smok-
ers (HR: 3.19, P < 0.001) not treated with immunosup-
pressive therapy, especially in females, in accordance with 
data from Cosnes et al[26]. Much emphasis was also placed, 
by some authors, on investigating the association between 
the amount of  smoking and the above variables in both 
CD and ulcerative colitis. In a recent publication, the 
authors[18] did not find a significant association between 
pack-years of  smoking and disease behavior or need for 
surgery. In addition, in a recent French publication[27], 
light smokers had higher resection rates compared to 
non-smokers in CD, suggesting that complete smoking 
cessation should be advised for all smokers with CD.
The key to explaining these conflicting results lies 
partly in the study by Cosnes et al[17], where the authors 
have demonstrated that immunosuppressive therapy 
neutralizes the effect of  smoking on the need for sur-
gery. Therefore, we aimed to analyze the effect of  
smoking in a more complex setting. After obtaining the 
results of  the univariate and Kaplan-Meier analyses, we 
performed both a logistic regression analysis adjusted to 
disease duration as an independent variable and a step-
wise proportional Cox regression analysis to investigate 
the relative weight of  the risk factors. In this analysis, 
perianal disease, smoking, steroid use, and AZA or 
AZA/biological therapy use before the behavior change 
were independently associated with time to disease be-
havior change. However, a partial recall bias, especially in 
the referral patients, where smoking habits were analyzed 
in a partially retrospective manner, cannot be excluded. 
Finally, the initial requirement for steroid use (OR: 3.1, 
95% CI: 2.2-4.4), an age below 40 years at diagnosis (OR: 
2.1, 95% CI: 1.3-3.6), and the presence of  perianal disease 
(OR: 1.8, 95% CI: 1.2-2.8) were associated with the de-
velopment of  disabling disease in the study by Beaugerie 
et al[21] The positive predictive values of  disabling disease 
in patients with two and three predictive factors for dis-
abling disease were 0.91 and 0.93, respectively. Nonethe-
less, the prevalence of  disabling disease was approximately 
80.5% at 5 years in the entire patient group, which makes 
these criteria less valuable in clinical practice. Moreover, 
the authors classified the need for immunosuppressive 
therapy as one potential disabling factor, which in light 
of  the present study, is rather controversial. In the pres-
ent study, prior steroid use was an independent predictor 
of  time to change in disease behavior. However, again, 
because of  the high prevalence of  overall steroid use, the 
confidence interval is wide and, consequently, the clinical 
usefulness of  this marker is relatively low. 
In adults, early postoperative use of  AZA at a dose 
of  2-2.5 mg/kg per day seemed to delay postoperative 
recurrence in comparison to a historical series or placebo 
groups in randomized, controlled trials[19]. Furthermore, 
in a recent withdrawal study by the GETAID group[20], 
the authors provided evidence for the benefit behind 
long-term AZA therapy beyond 5 years in patients with 
prolonged clinical remission. The most convincing 
data to support the benefit from early use of  AZA, 
however, comes from the pediatric literature[28], where 
in a randomized, controlled trial in 55 children, early 
6-mercaptopurine use was associated with a significantly 
lower relapse rate (only 9%) compared with 47% of  
controls (P = 0.007). Moreover, the duration of  steroid use 
was shorter (P < 0.001) and the cumulative steroid dose 
lower at 6, 12 and 18 mo (P < 0.01). More recently, also in 
a pediatric setting, this strategy was found to be associated 
with a lower hospitalization rate[29]. Similarly, in the present 
study, early AZA or AZA/biological therapy was an 
independent preventive factor associated with decreased 
probability of  developing complicated disease behavior 
during the course of  the disease (HR: 0.46 and 0.43).
In conclusion, in the present study, we have shown 
that the complex analysis of  disease phenotype, 
medication history, and smoking habits is needed, in 
order to study the factors associated with change in 
disease behavior in patients with IBD. Our data suggest 
that perianal disease, current smoking, prior steroid use, 
early AZA or AZA/biological therapy are predictors of  
disease behavior change in patients with CD.
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